As big pharma continues its trend of targeting biotech-discovered technology to fill the mega-drugmakers' depleting pipelines - with preclinical work becoming even more frequently eyed within that scope - Swiss manufacturer Novartis AG is the latest to take aim, inking a deal with GenVec Inc. potentially worth more than $213.6 million. (BioWorld Today)